课题基金 / 基金详情

Project 2: Serologic and molecular determinants of COVID-19 severity and immune protection

Project 2: Serologic and molecular determinants of COVID-19 severity and immune protection
项目 2:COVID-19 严重程度和免疫保护的血清学和分子决定因素
批准号:
10688394
负责人:
Linda J. Saif
金额:
$59.98万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-09-18 至 2024-11-30
关键词:
2019-nCoVACE2AgeAnimalsAntibodiesAntibody ResponseAntibody-Dependent EnhancementBindingBiological AssayBloodCOVID-19COVID-19 monitoringCOVID-19 pandemicCOVID-19 severityChildClinicalCommon ColdDataData SetDevelopmentDiagnosticDiseaseDisease OutcomeElderlyEnzyme-Linked Immunosorbent AssayEpitopesExposure toFamilyFrequenciesFutureGeneral PopulationGenesGeneticGenetic PolymorphismGenetic TranscriptionGoalsHouseholdHumanImmuneImmune responseImmunityImmunoglobulin AImmunoglobulin GImmunoglobulin IsotypesImmunoglobulin MImmunologic FactorsImmunologistImmunoprecipitationIndividualInfectionInfection preventionIntegration Host FactorsKineticsKnowledgeLeadLinkLuciferasesMeasuresMediatingMiddle East Respiratory Syndrome CoronavirusMolecularMucosal Immune ResponsesMucous MembraneMutationOpen Reading FramesOutcomePatientsPatternPeptidesPopulationPrevalencePrevention strategyProteinsProtocols documentationPublic HealthReverse Transcriptase Polymerase Chain ReactionRiskSARS coronavirusSARS-CoV-2 antibodySARS-CoV-2 infectionSARS-CoV-2 pathogenesisSARS-CoV-2 transmissionSamplingSerologySerology testSerumSeveritiesSeverity of illnessSourceSpecificitySymptomsTestingVaccinatedVaccineeVaccinesViralViral ProteinsVirusbetacoronaviruscareerco-infectioncohortcomorbiditycoronavirus diseasefirst respondergene inductionhigh riskhuman coronavirusimproved outcomeinfection riskinnovationinsightmembermucosal siteneutralizing antibodynovelresponsescreeningseropositivesevere COVID-19transcriptometranscriptome sequencingtumor-immune system interactionsvaccine-induced immunity

项目摘要

项目成果

Linda J. Saif的其他基金

相似基金

相关文献

中文摘要
翻译
项目二总结
英文摘要
Project 2 Summary PROJECT 2. Serologic and molecular determinants of COVID-19 severity and immune protection. Unresolved scientific questions remain about how the type, kinetics and duration of SARS-CoV-2 serologic responses correlate with patient age, disease severity, protective immunity, and risk of spread to close contacts. Our overall goal is to utilize the well-annotated STOP-COVID data sets and longitudinal samples collected from the first-responder cohort (at high-risk for re-exposure) and family contacts (Project 1, Core B) to advance understanding of the specific host and viral factors that underlie long-lasting and protective serologic responses. Our three highly interactive aims include: to identify differences in virus neutralizing (VN) antibody isotypes and their target viral proteins/peptides/epitopes; to assess cross-protective immunity versus disease exacerbation by antibodies to common cold CoVs; and to probe, by virus-host transcriptome analysis, how SARS-CoV titer or sequence and initial immune response at mucosal sites or blood interrelate with disease outcomes and the above serologic responses. Aim 1: Define immunoglobulin isotypes, titer, target proteins and viral neutralization activity of SARS-CoV-2 specific Abs and their correlations with disease severity and protection: We will utilize VN assays (VNA) and a luciferase immunoprecipitation assay to identify VN antibody isotype specificities and their immunodominant and unique target viral proteins/peptides/epitopes relevant to disease severity and protection. Expected outcomes include data that delineate the temporal antibody isotypes and viral targets to refine protocols for serologic testing that align with protective immunity. Aim 2: Determine the impact of common cold CoVs (CCCoV) and SARS-CoV-2 specific antibodies on COVID-19 protection and disease severity in a high-exposure risk cohort of first responders and their household contacts. Diagnostic serum samples will be used in innovative ELISA platforms directed against unique and conserved CCCoV peptides, and Spike pseudotyped CCCoV to assess CCCoV antibody responses. Expected outcomes include original data on whether pre-existing CCCoV antibodies relate to COVID-19 clinical symptoms, severity or strain specificity of SARS-CoV-2 infection (Aim 3), or re-infection risk. Aim 3. Correlate patterns of mucosal and serologic immune responses with virus and host genetics. We will utilize a novel targeted host-SARS-CoV-2 RNA sequencing assay (CoV-DXVX) to assess whether virus titer or functional alterations in SARS-CoV-2 S1, S2, N proteins or other ORFs impact disease presentation, progression and outcome. Host response measured by the profile and strength of mucosal or blood immune gene induction will be correlated with the duration, type and protective ability of these serologic responses and with the ones above. Once vaccines are deployed to our first-responder cohort, all 3 aims will pivot to analyze how the above serologic response profiles and host immune gene induction differ in vaccinated SARS-CoV-2 seronegative and seropositive individuals compared with the naturally-infected individuals.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Rotavirus Reverse Genetics System to Study Viral Pathogenesis and Receptor Interactions
  • 批准号:
    10739026
  • 项目类别:
  • 资助金额:
    $19.69万
  • 财政年份:
    2023
  • 负责人:
    Linda J. Saif
  • 依托单位:
Project 2: Serologic and molecular determinants of COVID-19 severity and immune protection
  • 批准号:
    10222411
  • 项目类别:
  • 资助金额:
    $81.82万
  • 财政年份:
    2020
  • 负责人:
    Linda J. Saif
  • 依托单位:
The impact of vitamin A on the gut-mammary gland-secretory IgA axis during enteric viral infections
  • 批准号:
    10427171
  • 项目类别:
  • 资助金额:
    $46.05万
  • 财政年份:
    2018
  • 负责人:
    Linda J. Saif
  • 依托单位:
The impact of vitamin A on the gut-mammary gland-secretory IgA axis during enteric viral infections
  • 批准号:
    9759974
  • 项目类别:
  • 资助金额:
    $44.7万
  • 财政年份:
    2018
  • 负责人:
    Linda J. Saif
  • 依托单位:
国内基金
海外基金
ACE2/AGXT2信号轴在甲基异柳磷诱导斑马鱼神经发育异常过程中的作用机制研究
  • 批准号:
    JCZRLH202600625
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位:
ACE2 Ser623磷酸化调控MED1促VSMCs功能损伤在移植血管重构中的作用及机制研究
  • 批准号:
    2026JJ50619
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    翁春艳
  • 依托单位:
新型蝙蝠MERS簇冠状病毒HKU5的ACE2细胞受体识别及其分子机制研究
铁皮石斛通过肠道 ACE2 修复 Trp/GPR142 介 导“肠-胰岛 ”轴血糖调控功能的降糖机制研 究
  • 批准号:
    Y24H280055
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    颜美秋
  • 依托单位: